November 03, 2015
Mylan has infringed five of AstraZeneca's patents by filing an abbreviated new drug application with the U.S. Food and Drug Administration to make a generic version of AstraZeneca's blood thinner Brilinta, according to a suit filed Monday in West Virginia federal court.